125 related articles for article (PubMed ID: 37993078)
1. Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19.
Hou L; Zhao Y; Zhao S; Zhang X; Yao X; Yang J; Wang Z; Chan ECY; Liu S
Chem Biol Interact; 2024 Jan; 387():110811. PubMed ID: 37993078
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions.
Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X
Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929
[TBL] [Abstract][Full Text] [Related]
3. Contributions of UDP-Glucuronosyltransferases to Human Hepatic and Intestinal Metabolism of Ticagrelor and Inhibition of UGTs and Cytochrome P450 Enzymes by Ticagrelor and its Glucuronidated Metabolite.
Liu S; Hou L; Li C; Zhao Y; Yao X; Zhang X; Tian X
Front Pharmacol; 2021; 12():761814. PubMed ID: 34721047
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 2B6 and UDP-Glucuronosyltransferase Enzyme-Mediated Clearance of Ciprofol (HSK3486) in Humans: The Role of Hepatic and Extrahepatic Metabolism.
Zhou Y; Dong H; Fan J; Zhu M; Liu L; Wang Y; Tang P; Chen X
Drug Metab Dispos; 2024 Jan; 52(2):106-117. PubMed ID: 38071562
[TBL] [Abstract][Full Text] [Related]
5. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
[TBL] [Abstract][Full Text] [Related]
6. An investigation of the metabolic activity, isozyme contribution, species differences and potential drug-drug interactions of PI-103, and the identification of efflux transporters for PI-103-
Gao L; Qin Z; Zhang B; Yin Z; Zhang X; Yang J
RSC Adv; 2020 Mar; 10(16):9610-9622. PubMed ID: 35497201
[TBL] [Abstract][Full Text] [Related]
7. Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model.
Ramsden D; Perloff ES; Whitcher-Johnstone A; Ho T; Patel R; Kozminski KD; Fullenwider CL; Zhang JG
Drug Metab Dispos; 2022 Feb; 50(2):114-127. PubMed ID: 34789487
[TBL] [Abstract][Full Text] [Related]
8. Regioselective glucuronidation of the isoflavone calycosin by human liver microsomes and recombinant human UDP-glucuronosyltransferases.
Ruan JQ; Yan R
Chem Biol Interact; 2014 Sep; 220():231-40. PubMed ID: 25044472
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.
den Braver-Sewradj SP; den Braver MW; Baze A; Decorde J; Fonsi M; Bachellier P; Vermeulen NPE; Commandeur JNM; Richert L; Vos JC
Eur J Pharm Sci; 2017 Nov; 109():96-110. PubMed ID: 28778465
[TBL] [Abstract][Full Text] [Related]
10. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
Shiraga T; Yajima K; Suzuki K; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
Drug Metab Dispos; 2012 Feb; 40(2):276-82. PubMed ID: 22031623
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
Kim S; Kim DK; Shin Y; Jeon JH; Song IS; Lee HS
Molecules; 2020 Oct; 25(19):. PubMed ID: 33050066
[TBL] [Abstract][Full Text] [Related]
12. Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5'-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes.
Choi WG; Park R; Kim DK; Shin Y; Cho YY; Lee HS
Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32131538
[TBL] [Abstract][Full Text] [Related]
13. Glucuronidation of mono(2-ethylhexyl) phthalate in humans: roles of hepatic and intestinal UDP-glucuronosyltransferases.
Hanioka N; Kinashi Y; Tanaka-Kagawa T; Isobe T; Jinno H
Arch Toxicol; 2017 Feb; 91(2):689-698. PubMed ID: 27071666
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes.
Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC
Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib Carries the Risk of Drug-Drug Interactions
Wang Z; Jiang L; Wang X; Yin H; Wang Z; Lv X; Liu Y
Curr Drug Metab; 2022; 23(11):912-919. PubMed ID: 36306450
[TBL] [Abstract][Full Text] [Related]
16. Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver.
Zhang Y; Sato R; Fukami T; Nakano M; Nakajima M
Xenobiotica; 2021 Dec; 51(12):1352-1359. PubMed ID: 34779706
[TBL] [Abstract][Full Text] [Related]
17. Traditional Herbal Formulas to as Treatments for Musculoskeletal Disorders: Their Inhibitory Effects on the Activities of Human Microsomal Cytochrome P450s and UDP-glucuronosyltransferases.
Jin SE; Seo CS; Shin HK; Ha H
Pharmacogn Mag; 2016; 12(48):241-252. PubMed ID: 27867264
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Kinetic Characterization of Axitinib Metabolism.
Zientek MA; Goosen TC; Tseng E; Lin J; Bauman JN; Walker GS; Kang P; Jiang Y; Freiwald S; Neul D; Smith BJ
Drug Metab Dispos; 2016 Jan; 44(1):102-14. PubMed ID: 26512042
[TBL] [Abstract][Full Text] [Related]
19. Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT1A1, 1A3 and 1A8.
Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2006; 31(4):299-309. PubMed ID: 17315542
[TBL] [Abstract][Full Text] [Related]
20. Potential Determinants for Metabolic Fates and Inhibitory Effects of Isobavachalcone Involving in Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Efflux Transporters.
Qin Z; Wang P; Duan S; Wan X; Xing H; Yang J; Zhang X; Yao Z; Yao X
J Pharm Sci; 2021 May; 110(5):2285-2294. PubMed ID: 33610566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
